14 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters”
The compound (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile can stimulate hair growth and reduce oil production when applied topically.
PP405 is expected to be more expensive than finasteride and minoxidil initially due to patentprotection, but not as costly as life-saving medications like Ozempic. The price may decrease after the patent expires, but initially, it might be around $100 per month, making it potentially unaffordable for many.
First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.
A doctor criticized the use of Finasteride for hair loss, suggesting Minoxidil and a hair transplant instead, despite the patient experiencing no side effects from Finasteride. The patient disagreed, arguing that Minoxidil doesn't address the root cause and that Finasteride is necessary to protect donor hair in transplants.